Ozempic, the globally sought-after semaglutide injection that has dominated conversations around diabetes care and weight loss, has finally entered the Indian market. With it, an immediate surge of ...

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

With India facing over 101 million cases of diabetes and rising obesity levels, the drug could play a significant role in ...

Ozempic, the blockbuster weight-loss drug by Novo Nordisk, was launched in India on Friday (December 12). In India, the drug will be marketed for adults with type-2 diabetes, unlike in the US and ...

While Ozempic offers proven benefits for blood sugar control, weight management, and cardiovascular protection, its arrival ...

Ozempic, a GLP-1 receptor agonist, has officially launched in India, offering a new treatment option for type 2 diabetes.

Looking to expand its footprint in the booming glucagon-like peptide (GLP-1) market, Danish drugmaker Novo Nordisk has ...

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...